ABSTRACT
INTRODUCTION
Herbal medicines have gained global importance over the past few decades. [1] [2] [3] [4] [5] [6] Their medicinal and economic benefits have been accepted in both developing and industrialized nations, particularly in developing countries, where they are being traditionally used against various disease complications. [7] [8] [9] Herbal remedies, in the form of a single herb or polyherbal formulations, play a prime role in the healthcare system because of their wide biological activity, easy accessibility, cost effectiveness and safe usage. [10] [11] [12] However, these medicines have not yet integrated into the modern clinical practice due to lack of experimental and clinical evidence on their quality. [13, 14] The complexity of polyherbal formulations impose a greater challenge in establishment of their quality, efficacy and safety, compared to single herbal counterparts. [15] [16] [17] Thus, it becomes important to standardize the herbal drugs by various parameters and sophisticated techniques to ensure their quality, safety and efficacy. [18] [19] [20] Various regulatory bodies such as World Health Organization (WHO), European Agency for the Evaluation of Medicinal Products (EMEA), United States Pharmacopeia (USP), and Department of AYUSH, Government of India, have provided the standardization guidelines for development of herbal preparations. [21, 22] In the present work, we have standardized a polyherbal formulation (HC9) that we previously reported to possess antioxidant and cytotoxic activity. 1 It is composed of nine medicinal herbs that include Picrorhiza kurroa, Cyperus rotundus, Zingiber officinale, Cedrus deodara, Tinospora cordifolia, Holarrhena antidysenterica, Swertia chirata, Cissampelos pareira and Hemidesmus indicus ( Table 1 ). The formulation was prepared based on the reported anticancer and immunomodulatory activity of the individual herbs present in it ( Table 2) . We have standardized each herbal component of HC9 and the composite formulation with respect to their marker compounds. We have also evaluated the physicochemical and phytochemical parameters of HC9. After standardizing HC9, we have compared the cytotoxic activity of HC9 with its individual components in human breast cancer (MCF-7 and MDA MB-231) and non-cancerous transformed (HEK-293 and HaCaT) cell lines. This was done to evaluate whether the individual components of HC9 were more active than the whole formulation.
MATERIALS AND METHODS

Chemicals and reagents
Tissue culture plasticware was purchased from BD Biosciences (CA, USA) and Axygen Scientific Inc (CA, USA). Dulbecco's Modified Eagles Medium (DMEM) powder, penicillin and streptomycin were obtained from Invitrogen/ Gibco (Grand Island, NY, USA). Fetal bovine serum (FBS) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylthiazolium bromide (MTT) were purchased from Sigma-Aldrich (St. Louis, MO). All other common solvents were procured from Qualigen Fine Chemicals (Mumbai, India) and HPTLC grade solvents were purchased from Merck (Mumbai, India). Reference marker compounds for High Performance Thin Layer Chromatography (HPTLC) analysis were obtained from the Natural Remedies Pvt Ltd (Bangalore, Karnataka-India) and Sigma-Aldrich (St. Louis, MO, USA). The solvents used for high-performance thin-layer chromatography (HPTLC) analysis were obtained from MERCK (Mumbai, India).
Collection, identification and authentication of plant materials
The whole/parts of all nine component herbs of HC9 were purchased from Shri Shailya Medi-Pharms (Solapur, Maharashtra, India). The individual bulk herb samples were stored in air-tight containers and kept in air-conditioned environment until further use. The samples were authenticated and validated macroscopically and microscopically in Department of Botany, Agharkar Research Institute (ARI), Pune (Maharashtra, India). Voucher specimens of herbs have been deposited at the Department of Botany, Agharkar Research Institute and Herbaria of Medicinal Plant Conservation Centre (MPCC), Pune (Table 1) .
Extract preparation
All nine herbs of HC9 were washed, dried and fine powdered separately. Ethanolic extracts of individual herbs were prepared by soxhlet extraction method. [1] For the preparation of HC9 formulation, equal parts of each powdered plant material of HC9 were mixed in 1:1 ratio and subjected to soxhlet extraction method using ethanol. The resulting extracts were centrifuged at 13000rpm for 15 min to remove the particulate matter. The supernatants were filter-sterilized using Swiney filter (pore size, 0.45 µm) and the resultant filtrates were stored in aliquots at -80°C until further use.
Organoleptic evaluation of HC9
The organoleptic characters of the powdered HC9 were evaluated by appearance, size, shape, color, texture, odor and taste according to the guidelines of Indian Pharmacopoeia. [47] 
Determination of physicochemical parameters of HC9
Physico-chemical parameters such as total ash content, total viable count, loss on drying of extract, ethanolextractable matter in the mixture of air-dried powder material, determination of pH, bulk density as well as specific gravity of HC9 extract were carried out at Indian Drug Research Institute (IDRI), Pune (Maharashtra, India) according to the prescribed standard methods in Indian Pharmacopoeia. [47] Preliminary phytochemical analysis of HC9
The preliminary phytochemical analysis of HC9 was done by Indian Drug Research Institute (IDRI), Pune (Maharashtra, India). The extract was screened to detect the presence of secondary metabolites such as alkaloids, carbohydrates, flavanoids, saponins, terpenoids, tannins and phenolic compounds. [47] HPTLC finger printing profile Identity of individual herbs and HC9 formulation was confirmed by detecting the presence of marker compounds such as picroside-I, nootkatone, 6-gingerol, matairesinol, berberine, connesine, swertiamarin, berberine and 2-hydroxy-4-methoxybenzaldehyde in P. kurroa, C. rotundus, Z.officinale, C. deodara, T. cordifolia, H. antidysenterica, S. chirata, C. pareira and H. indicus, respectively. Stocks and working solutions of different marker compounds were prepared in respective diluents (Table 3) . Standard (marker compounds) and samples (HC9 and nine individual herbs) were applied onto a thin layer chromatography (TLC) plate, using an automatic TLC sampler (Linomat 5) as described previously. [5] In brief, the samples (standards and test samples) were spotted as bands (8mm width) with a Camag (Muttenz, Switzerland) Hemilton microlitre syringe onto a precoated aluminum-backed silica gel 60F-254 plate (20 × 10cm; layer thickness 250μm; Merck, Darmstadt, Germany) using a Camag high-performance thin-layer chromatography (HPTLC) system equipped with an automatic TLC sampler (Linomat 5), TLC scanner 3, and integrated software Win-Cats version 4. A constant application rate (0.1μL/s) was employed and the space between the two bands was 6 mm. The respective working solutions of standards (Table 3) were applied to the TLC plate along with the test solution. Linear ascending development was carried out in 20cm × 10cm twin trough glass chamber pre-saturated with the respective mobile phase. The optimum chamber saturation time for the mobile phase was 20 min at room temperature. The chromatoplates were developed up to 80mm under chambersaturation conditions to get good resolution of phytochemical contents. Subsequent to development, TLC plates were dried in a current of air with the help of an air-dryer to evaporate solvents from the plates. The plates were examined using A Camag model III TLC scanner with CATS 4.0 integration software. Densitometric scanning was performed in the appropriate absorbance mode with a slit dimension of 6 × 0.45mm and ascanning speed of 10mm/s. A deuterium lamp was used as source of radiation. The amount of marker compounds present in HC9 was determined from the calibration curve obtained by plotting the concentration of standard against the peak area of test samples.
Cell lines
The human breast carcinoma cell lines, MCF-7 and MDA MB-231 and non-cancerous transformed cell lines, HEK-293 (Human Embryonic kidney) and HaCaT (Human Keratinocyte) used in the study were obtained from National Centre for Cell Science (NCCS), Pune, India. The cells were grown in DMEM containing 2mM L-glutamine supplemented with 10% fetal bovine serum and 100U/ml of penicillin-streptomycin. The cells were incubated in a humidified 5% CO2 incubator at 37°C. Non-tumorigenic normal mammary epithelial cell lineMCF-10A was a kind gift from Dr. Milind Vaidya (ACTREC, Mumbai). The cells were grown in DMEM:Ham's F12 (1:1) containing 2 mM L-glutamine supplemented with 10% fetal bovine serum, 100U/ml of penicillin-streptomycin, 10μg/ml insulin, 20ng/ml EGF and 0.5 mg/ml hydrocortisone.
The cells were incubated in a humidified 5% CO2 incubator at 37°C. [48] Cytotoxic Assay
Cytotoxicity of nine component herbs of HC9 and the whole formulation was determined in the cancerous and non-cancerous cell lines by MTT dye uptake. [49] Briefly, MCF-7, MDA-MB-231, HEK-293 HaCaT and MCF-10A cells were seeded at 1 × 10 5 /ml density in 96-well plates. Next day, the cells were incubated with various concentrations of HC9 and ethanolic extracts of individual herbs (0-160µg/ml) for 24 h and incubated in 5% CO2 incubator at 37°C. Next day, the MTT solution (5mg/ml) was added to each well and the cells were cultured for another 4 h at 37°C in 5% CO2 incubator. The formazan crystals formed were dissolved by addition of 90µl of SDS-DMF (20% SDS in 50% DMF). After 15 min, the amount of colored formazan derivative was determined by measuring optical density (OD) with the ELISA microplate reader (Biorad, Hercules, CA) at OD 570-630nm. The percentage viability was calculated as:
% Viability = [OD of treated cells/ OD of control cells]
× 100
Statistical analysis
IC 50 values were calculated by using Kyplot software. All the assays were performed in triplicates and repeated at least three times at different time points. The data has been presented as IC 50 values and mean ± SD.
RESULTS AND DISCUSSION
Organoleptic evaluation
The powdered HC9 was evaluated for its organoleptic properties. The results revealed that HC9 was dark green in color with characteristic odor, bitter taste and fine texture. These parameters form the basic criteria for selecting a raw drug. [54] Fine texture of powdered HC9 indicated the smoothness and surface uniformity that forms the primary character to assess the quality of a herbal drug. [50] Physico-chemical analysis HC9 was evaluated for total ash content, ethanol soluble extractive, loss on drying at 105ºC, pH, specific gravity and bulk density. All the values have been summarized in Table 4a . Physico-chemical analysis of HC9 revealed that the total ash content present in HC9 was 7.24%. The total ash values of the individual plant materials of HC9 have been reported to be in the range of 2-8% (Table 4b) . Determination of total ash value is an important criteria to judge the authenticity and purity of the crude drug. [50] It indicates total amount of inorganic material present in the drug after its complete incineration. A high ash value indicates contamination, substitution, adulteration during the preparation of drug. [51] The results indicated that HC9 has low inorganic material.
The percentage yield of alcohol-soluble extractive of HC9 was found to be 9.52% w/w. The alcohol-soluble extractive values of the individual plant materials in HC9 have been reported to be in the range of 4.5-18% (Table  4b ). The extractive value indicates the amount of active ingredient present in the given amount of plant material when extracted with respective solvent. [50] Less extractive value indicates addition of exhausted material, adulteration or incorrect processing during drying, storage or formulation preparation. The alcohol-soluble extractive of HC9 was found to be within the acceptable range.
Loss on drying at 105ºC of HC9 was found to be 7.18%. This value is indicative of amount of moisture content present in the drug. [51] The test for loss on drying actually determines water as well as volatile matter content in drug when subjected to heat. The high moisture content in herbal drugs endorses microbial as well as insect contamination. The low moisture content is always desirable for higher stability of drugs. Our results showed that the formulation could be stored for a long period and would not be easily contaminated with microbes. 51 The pH conventionally represents the acidity or alkalinity. HC9 (1% w/v solution) showed a pH of 6.1 indicating that the formulation was acidic in nature.
Bulk density, a measure used to describe packing of particles or granules, of HC9 was found to be around 0.50 g/ml. Lower value of density indicates good flow and higher value indicates poor flow properties of formulation. [50] The specific gravity of HC9 was found to be 0.801. All these values indicated that HC9 exhibited good flow properties.
Preliminary phytochemical evaluation
The preliminary phytochemical screening of HC9 demonstrated the presence of alkaloids, carbohydrates, flavanoids, saponins, tannins and phenolic compounds, and absence of terpenoids. These qualitative tests are used to detect the presence of functional groups, which play an important role in the biological activity of the drug. [49] HPTLC analysis of ethanolic extracts of individual components of HC9 and the composite formulation TLC fingerprinting profile followed by HPTLC analysis of component herb present in HC9 and the formulation was performed by using respective marker compounds swertiamarin and 2-hydroxy-4-methoxybenzaldehyde in the extracts (Table 6) . Similarly, HC9 showed Rf values corresponding to the presence of respective marker compounds in the formulation. Thus, all the component herbs of HC9 were authenticated and found to be present in the the formulation based on HPTLC analysis.
The amount of marker compounds present in the extracts of individual plants of HC9 and the formulation was also evaluated. P. kurroa, C. rotundus, Z. officinale, C. deodara, T. cordifolia, H. antidysenterica, S. chirata, C. pareira (Table 5 ). The finger printing profiles were developed in respective solvent systems as given in Table 3 and their corresponding peaks were recorded at respective Rf values. Table 6 Table 6 ). The overall results indicated that HC9 contained more amount of picroside-I, 6-gingerol, matairesinol and 2-hydroxy-4-methoxybenzaldehyde compared to the other marker compounds. Thus, the activity of HC9 could be due to the presence of high amounts of picroside-I, 2-hydroxy-4-methoxybenzaldehyde, 6-gingerol and matairesinol.
Effect of individual extracts and HC9 formulation on cell viability
After standardization of HC9, we wanted to compare its cytotoxic activity with the component herbs to know whether the individual components of HC9 were more active than the whole formulation. (Table 7) . HC9 was non-cytotoxic up to 160µg/ml concentration in non-cancerous cell lines and exhibited significant cytotoxicity in MCF-7 and MDA MB-231 at the same concentration (Supplementary data S1-S5). These results suggest that the standardized HC9 formulation was safe to non-cancerous cells and exhibited significant anticancer potential for breast cancer cells compared to the component herbs.
CONCLUSION
Standardization of the polyherbal formulation (HC9) was done according to Ayurvedic Pharmacopoeia of India guidelines (Department of AYUSH, Government of India). The present study may be used as a reference standard for quality control and standardization of polyherbal formulations that could help in strengthening the use of medicinal herbs. Our study suggests that compared to the component herbs, HC9 exhibited significant cytotoxicity in breast cancer cells without killing the non-cancerous cells. Further investigations are underway to identify the underlying mechanisms of antineoplastic activity of HC9 in breast cancer. 
